基于复制缺陷型PB2敲除病毒评估针对H1N1pdm09和B型流感病毒的季节性流感疫苗
研究开发了携带H1N1pdm09或B型病毒血凝素(HA)和神经氨酸酶(NA)片段的复制缺陷型PB2敲除(PB2-KO)流感病毒,并在小鼠中测试其疫苗潜力。两种PB2-KO病毒在表达PB2的细胞中高效增殖并表达嵌合HA,免疫小鼠可检测到病毒特异性IgG和IgA抗体,攻毒后临床体征 milder 且呼吸道病毒复制水平较低。结果表明这些PB2-KO病毒有潜力作为疫苗候选。
要点
- PB2-KO病毒在表达PB2的细胞中高效增殖并表达嵌合HA。
- 免疫小鼠产生病毒特异性IgG和IgA抗体。
- 攻毒后免疫小鼠临床体征 milder 且呼吸道病毒复制水平较低。
核心结论
- 这些PB2-KO病毒有潜力作为疫苗候选。
研究设计与样本
- 研究开发了携带H1N1pdm09或B型病毒HA和NA片段的复制缺陷型PB2-KO流感病毒,并在小鼠中测试其疫苗潜力。
主要发现
- 两种PB2-KO病毒在表达PB2的细胞中高效增殖并表达嵌合HA。
- 免疫小鼠可检测到病毒特异性IgG和IgA抗体。
- 攻毒后免疫小鼠临床体征 milder 且呼吸道病毒复制水平较低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination is the first line of protection against influenza virus infection in humans. Although inactivated and live-attenuated vaccines are available, each vaccine has drawbacks in terms of immunogenicity and safety. To overcome these issues, our group has developed a replication-incompetent PB2-knockout (PB2-KO) influenza virus that replicates only in PB2-expressing cells. Here we generated PB2-KO viruses possessing the hemagglutinin (HA) and neuraminidase (NA) segments from H1N1pdm09 or type B viruses and tested their vaccine potential. The two PB2-KO viruses propagated efficiently in PB2-expressing cells, and expressed chimeric HA as expected. Virus-specific IgG and IgA antibodies were detected in mice immunized with the viruses, and the immunized mice showed milder clinical signs and/or lower virus replication levels in the respiratory tract upon virus challenge. Our results indicate that these PB2-KO viruses have potential as vaccine candidates.
引用
- Ui H, Yamayoshi S, Uraki R, et al. Evaluation of seasonal influenza vaccines for H1N1pdm09 and type B viruses based on a replication-incompetent PB2-KO virus. Vaccine. 2017. PMID: 28285982. doi:10.1016/j.vaccine.2017.02.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。